REGN FY 2017 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5.9B+20.8% YoY

Gross Profit

$5.3B90.8% margin

Operating Income

$2.1B35.4% margin

Net Income

$1.2B20.4% margin

EPS (Diluted)

$10.34

Cash Flow

Operating Cash Flow

$1.3B

Free Cash Flow

$1.0B

Stock-Based Comp.

$507M

Balance Sheet

Total Assets

$8.8B

Total Liabilities

$2.6B

Stockholders' Equity

$6.1B

Cash & Equivalents

$813M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.9B	$4.9B	+20.8%
Gross Profit	$5.3B	$4.5B	+19.6%
Operating Income	$2.1B	$1.3B	+56.3%
Net Income	$1.2B	$896M	+33.8%